Develops and markets pharmaceutical products for various therapeutic areas, including oncology, cardiovascular, and central nervous system disorders. Now — the numbers.
This is an established company with proven profits.
Average growth of 15% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $2.2B would still be left in the vault — a solid cushion for hard times.
The market pays 15.7× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
The stock trades below its recent peak — about 8% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 15% a year on average.
There is $3.7B in the vault; even if every debt were paid off, $2.2B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.